2-chloro-3-methyl-6-nitroquinoline | 132118-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-chloro-3-methyl-6-nitroquinoline
• CAS: 132118-33-3
• 化学式: C₁₀H₇ClN₂O₂
• 分子量: 222.631
• InChiKey: NHIDQEPZBFZZKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-3-methyl-6-nitroquinoline 在 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-甲基-6-硝基-2-哌嗪-1-基喹啉
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter: Part 3. † †Part 2. See ref 1. A potential 5-HT transporter imaging agent, 3-(3-[ 18 F]fluoropropyl)-6-nitroquipazine

  摘要：

  3-(3-[F-18]Fluoropropyl)-6-nitroquipazine ([F-18]FPNQ) as a 5-HT transporter imaging agents was designed, synthesized, and evaluated. FPNQ was selected due to its potent in vitro biological activity (K-i = 0.32 nM) in rat brain cortical membranes. The F-18-labeled FPNQ was prepared by reaction of the propyl mesylate as a precursor with tetra-n-butylammonium [F-18]fluoride generated under NCA conditions. The precursor mesylate was synthesized from commercially available hydrocarbostyril in nine steps in 21% overall yield. The specific activity of the [F-18]FPNQ determined by radioreceptor assay was 27.0 GBq/mumol. Tissue distribution studies in mice showed the highest uptake in the frontal cortex (5.79 %ID/g) at 60 min post-injection. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.009
• 作为产物：
  描述：

  3-甲基-3,4-二氢-2(1H)-喹啉酮 在 硫酸 、 硝酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 三氯氧磷 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.08h， 生成 2-chloro-3-methyl-6-nitroquinoline
  参考文献：
  名称：

  Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter: Part 3. † †Part 2. See ref 1. A potential 5-HT transporter imaging agent, 3-(3-[ 18 F]fluoropropyl)-6-nitroquipazine

  摘要：

  3-(3-[F-18]Fluoropropyl)-6-nitroquipazine ([F-18]FPNQ) as a 5-HT transporter imaging agents was designed, synthesized, and evaluated. FPNQ was selected due to its potent in vitro biological activity (K-i = 0.32 nM) in rat brain cortical membranes. The F-18-labeled FPNQ was prepared by reaction of the propyl mesylate as a precursor with tetra-n-butylammonium [F-18]fluoride generated under NCA conditions. The precursor mesylate was synthesized from commercially available hydrocarbostyril in nine steps in 21% overall yield. The specific activity of the [F-18]FPNQ determined by radioreceptor assay was 27.0 GBq/mumol. Tissue distribution studies in mice showed the highest uptake in the frontal cortex (5.79 %ID/g) at 60 min post-injection. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.009

文献信息

• Quinoline derivatives, their preparation and pharmaceutical compositions comprising the same
  申请人：Chi Dae-Yoon

  公开号：US20050165006A1

  公开（公告）日：2005-07-28

  Novel quinoline derivatives were prepared and evaluated their pharmaceutical activities. The quinoline derivatives according to the present invention effectively bind serotonin transporter (SERT) which is called serotonin reuptake site. Serotonin is one of the neurotransmitter and the lack of its concentration in synapse cause the depression. The quinoline derivatives in this invention can interrupt reuptake of serotonin into presynaptic neuron resulting the increasement of concentration of serotonin in synapse as well as stimulating the signal through the binding with serotonin recepter. Thus, they can be used for the prevention and treatment of mental disorder, especially depression, caused by the deficiency of serotonin concentration in synapse.

  通过本发明制备了新型喹啉衍生物，并评估了它们的药物活性。本发明的喹啉衍生物能够有效地结合血清素转运体（SERT），也称为血清素再摄取位点。血清素是一种神经递质，如果突触中缺乏其浓度，则会导致抑郁症。本发明中的喹啉衍生物可以中断血清素重新摄取到突触前神经元中，从而增加突触中血清素的浓度，并通过与血清素受体结合刺激信号。因此，它们可以用于预防和治疗由突触中血清素浓度不足引起的心理障碍，特别是抑郁症。
• 2-Aminoquinoline compounds
  申请人：DeVita J. Robert

  公开号：US20050026915A1

  公开（公告）日：2005-02-03

  The present invention is concerned with compounds of the general Formula I: and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists. As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington's disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.

  本发明涉及一般式I的化合物及其药学上可接受的盐，其作为黑色素浓集激素受体拮抗剂，特别是MCH-1R拮抗剂而有用。因此，本发明的化合物可用于治疗或预防与过度食物摄入及其并发症有关的肥胖症或进食障碍，骨关节炎，某些癌症，艾滋病消耗症，消瘦，衰弱（尤其是老年人），精神障碍，压力，认知障碍，性功能，生殖功能，肾功能，运动障碍，注意力缺陷障碍（ADD），物质滥用障碍和运动障碍，亨廷顿病，癫痫，记忆功能和脊髓肌萎缩。因此，式I的化合物可用于治疗这些疾病，并用于制造用于治疗这些疾病的药物。本发明还公开了包含式（I）中的一种化合物作为活性成分的制药配方，以及制备这些化合物的过程。
• 2-AMINOQUINOLINE COMPOUNDS
  申请人：Merck & Co., Inc.

  公开号：EP1450801A2

  公开（公告）日：2004-09-01
• US7084156B2
  申请人：——

  公开号：US7084156B2

  公开（公告）日：2006-08-01
• [EN] 2-AMINOQUINOLINE COMPOUNDS<br/>[FR] COMPOSÉS DE 2-AMINOQUINOLINE
  申请人：MERCK & CO INC

  公开号：WO2003045313A2

  公开（公告）日：2003-06-05

  The present invention is concerned with compounds of the general Formula I : and pharmaceutically acceptable salts thereof, which are useful as melanin concentrating hormone receptor antagonists, particularly MCH-1R antagonists.As such, compounds of the present invention are useful for the treatment or prevention of obesity or eating disorders associated with excessive food intake and complications thereof, osteoarthritis, certain cancers, AIDS wasting, cachexia, frailty (particularly in elderly), mental disorders stress, cognitive disorders, sexual function, reproductive function, kidney function, locomotor disorders, attention deficit disorder (ADD), substance abuse disorders and dyskinesias, Huntington s disease, epilepsy, memory function, and spinal muscular atrophy. Compounds of formula I may therefore be used in the treatment of these conditions, and in the manufacture of a medicament useful in treating these conditions. Pharmaceutical formulations comprising one of the compounds of formula (I) as an active ingredient are disclosed, as are processes for preparing these compounds.